GE Healthcare, M+W Group sign biopharmaceuticals manufacturing deal

The collaboration will help various countries across the globe in making them self-sufficient in the manufacture of vital biopharmaceuticals such as vaccines, insulin and biosimilars, thus reducing the dependence on imports.

Both the companies will provide governments and pharmaceutical companies an integrated, cost-competitive approach to construct biopharmaceutical manufacturing plants, there by catering to the increasing demand for potentially life-saving treatments.

The deal is said to be in line with GE’s healthymagination initiative which lays emphasis on reducing cost, increasing access and improving quality in healthcare.